Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy
Summary
- Eligibility
- for people ages 18-75 (full criteria)
- Location
- at Orange, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Ra Pharmaceuticals
- ID
- NCT04025632
- Phase
- Phase 2
- Study Type
- Interventional
- Last Updated